Johnson & Johnson is evaluating the costs and strategic benefits of acquiring a biopharmaceutical company specializing in rare diseases for $4 billion. The acquisition is expected to expand Johnson & Johnson's product portfolio and generate $700 million in annual revenue.

Requirements:

• Present the acquisition cost and revenue projections in bullet points.
• Calculate the total investment and potential ROI for acquiring the biopharmaceutical company.
• Analyze the strategic fit and market potential of rare disease treatments.
• Discuss regulatory considerations and market access in biopharmaceuticals.
• Evaluate the financial impact on Johnson & Johnson's cash flow and earnings per share.
• Recommend integration strategies to leverage synergies and accelerate growth.